Quick Answer
Viridian Therapeutics, Inc.DE reported Stockholders Equity of $722.17 million for fiscal year 2025.
Viridian Therapeutics, Inc.DE Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $722.17M | +7.5% |
| 2024 | $671.64M | +51.9% |
| 2023 | $442.02M | +11.9% |
| 2022 | $395.06M | +110.5% |
| 2021 | $187.72M | +56.4% |
| 2020 | $120.04M | +661.9% |
| 2019 | $15.75M | -69.3% |
| 2018 | $51.34M | +33.3% |
| 2017 | $38.51M | +162.2% |
| 2016 | -$61.92M | -36.7% |
| 2015 | -$45.29M | -856.0% |
| 2014 | $5.99M | +125.1% |
| 2013 | -$23.89M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $502.97M | -28.9% | -2.4% |
| June 30, 2025 | $515.17M | -2.7% | -14.8% |
| March 31, 2025 | $604.47M | +3.8% | -10.0% |
| December 31, 2024 | $671.64M | +51.9% | -5.1% |
| September 30, 2024 | $707.50M | +149.5% | +33.7% |
| June 30, 2024 | $529.34M | +67.6% | -9.1% |
| March 31, 2024 | $582.53M | +66.2% | +31.8% |
| December 31, 2023 | $442.02M | +11.9% | +55.9% |
- Viridian Therapeutics, Inc.DE showed an increase of +7.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Viridian Therapeutics, Inc.DE’s stockholders equity has grown by 3123.3% (from -$23.89 million to $722.17 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: